Skip to main content
. 2007 Aug 30;110(13):4417–4426. doi: 10.1182/blood-2007-05-092098

Figure 1.

Figure 1

Akt expression in WM (Waldenstrom macroglobulinemia) cells. (A) Baseline phosphorylation expression of Akt serine 473 in freshly selected CD19 + bone marrow cells from patients with WM disease (N = 4) compared with bone marrow CD19 + cells from healthy donors (NBM) (N = 2). β-actin was used as a control. (B) Baseline phosphorylation expression of Akt serine 473 was assessed in BCWM.1 cell line (BC), MM.1S cell line (MM), and several IgM-secreting cell lines: WM-WSU (WSU), MEC-1 (MEC), RL, by Western blotting. α-tubulin antibody is always used as a control. Specific inhibition of Akt pathway affects survival of WM cells. (C) BCWM.1 cells were cultured with triciribine for 6 hours with doses that range from 1 to 10 μM. Whole cell lysates were subjecting to Western blotting using anti–p-Akt ser473, -Akt, –p-ERK, and α-tubulin antibodies. (D) Triciribine (1 to 50 μM) induces growth inhibition and cytotoxicity in BCWM.1 cells at 48 hours by the [3H]-thymidine uptake assay and the MTT assay. (E) BCWM.1 cells were transduced with 2 Akt shRNA for 48 hours. Mock: control plasmid; 62 and 63 represent shRNA that target 2 different sequences of Akt gene. Whole cell lysates were subjected to Western blotting using anti–p-Akt, -Akt, -p-S6R, –p-GSK3α/β, and α-tubulin antibodies.